Expression of topoisomerase II, BCL-2, and Ki-67 in ovarian cancer tissue and their effects on the development and prognosis of ovarian cancers


Akyurek E. N., Avsar A. F. Y., Ural U. M., Kilicarslan A., Yildirim M.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, cilt.38, sa.5, ss.675-679, 2017 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 5
  • Basım Tarihi: 2017
  • Doi Numarası: 10.12892/ejgo3370.2017
  • Dergi Adı: EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.675-679
  • Recep Tayyip Erdoğan Üniversitesi Adresli: Hayır

Özet

Purpose: The objective of this study was to evaluate the role of the expression of topoisomerase II, BCL-2, and Ki-67 in an ovarian tissue and their effects on the development and the prognosis of ovarian cancers. Materials and Methods: The study consisted of 38 female patients with ovarian cancers. Patients' characteristics, tumor type, stage, and the grade of the disease, and topoisomerase II, Bcl2, and Ki-67 values in ovarian tissue were compared. Results: Extensivenesses of topoisomerase II and Ki-67 staining in early -stage disease were found statistically different from those in the advanced stage diseases (for topoisomerase II, 60.38 33.87% vs 85 8.5%, p = 0.017, for Ki-67; 25.07 +/- 25.04% vs 51 +/- 25.29%,p = 0.012). Differences of Bcl-2 staining between two groups were not significant (30.38 +/- 38.82 % vs 18.2 +/- 30.58%, p = 0.377). Conclusions: Expressions of topoisomerase II and Ki-67 in ovarian cancer tissues were associated with advanced stage diseases and expression of Bcl-2 refers to good histological grade in patients.